A Phase I Study to Assess Safety and Tolerability of a Live Biotherapeutic Product (SVT-1B149) in the treatment of Chronic Functional Constipation in Adult Participants.

Servatus Ltd0 sites38 target enrollmentOctober 19, 2020

ConditionsFunctional Constipation (FC)Irritable Bowel Syndrome - Constipation (IBS-C)Idiopathic Constipation (IC)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Functional Constipation (FC)
Sponsor: Servatus Ltd
Enrollment: 38
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

October 19, 2020

End Date

April 3, 2022

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Servatus Ltd

Eligibility Criteria

Inclusion Criteria

•Male and female Participants aged 18 years or older, capable of providing informed consent and able to attend the Princess Alexandra Hospital as required for the study;
•Determined by medical history, physical examination, vital signs and clinical judgement of the Investigator to be medically healthy and eligible for inclusion into the study;
•Confirmation of diagnosis of IBS\-C or IC according to Rome III criteria;
•Able to adhere to the medication guidelines prior to undertaking the glucose breath test which includes:
•\- No antibiotic use 2 weeks prior to the procedure;
•\- No smoking or eating any food from 10 pm before the procedure until after the test is finished.
•Females of childbearing potential (FOCBP) must have a negative pregnancy test at the Baseline Visit. While on the study, FOCBP who engage in activity in which conception is possible, must use one of the approved contraceptive options described below:
•I.Hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring);
•II.Intrauterine device (IUD);
•III.Tubal Ligation;

Exclusion Criteria

•Participants who meet any of the following criteria will be ineligible for enrolment into the study:
•Diarrhoea predominant or alternating IBS;
•Immunocompromised Participants, or those with known or suspected history of immunodeficiency, as determined by medical history review, physical examination and/or laboratory findings;
•History of severe adverse reaction including but not limited to anaphylaxis (or a suspicion of this by the Investigator) to any products containing bacterial species, any component of SVT\-1B149 or to any antibiotic commonly used to treat bacterial infections;
•Any history of anti\-tumour necrosis factor (TNF) treatment or other immunosuppressant medications;
•Current use of corticosteroids: Greater than or equal to 15mg/daily or oral prednisolone (or equivalent) and/or history of intermittent corticosteroid usage of greater than or equal to 40mg/daily or oral prednisolone (or equivalent) of greater than 3 days in the last 3 months;
•Use of oral antibiotics within 2 weeks of the Baseline Visit (Day 0\) and for the study duration;
•Females who are pregnant or breastfeeding or planning on becoming pregnant for the study period (treatment and follow\-up periods);
•Any condition that, in the opinion of the Investigator, contraindicates participation in this study or poses an additional risk to the Participant including any known and/or suspected medical or psychiatric conditions, history of active peptic ulcer disease and/or gastroesophageal disease, severe gastritis or presence of alarm symptoms.